Projects per year
Personal profile
Chinese Name
易威伸
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
-, Bachelor, University of Cambridge
Master, University of Cambridge
Chemistry, PhD, University of Oxford
Keywords
- QD Chemistry
- RM Therapeutics. Pharmacology
Fingerprint
Dive into the research topics where Wei Shen AIK is active. Topic labels come from the works of this scholar.
- 1 Similar Scholars
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
-
Structure-based inhibitor development targeting RNA epitranscriptomic modifications
1/09/19 → 31/08/22
Project: Research project
-
Mechanisms of substrate recognition and N6-methyladenosine demethylation revealed by crystal structures of ALKBH5-RNA complexes
Kaur, S., Tam, N. Y., McDonough, M. A., Schofield, C. J. & Aik, W. S., 22 Apr 2022, In: Nucleic Acids Research. 50, 7, p. 4148-4160 13 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Ribonucleoproteins for RNA Therapeutics Delivery
AIK, W. S., 1 Jan 2022, IPC No. C12-AW-U4RN-TW01, 12 Mar 2021, Priority date 13 Mar 2020, Priority No. TW 110109035Research output: Patent
-
Reconstitution and biochemical assays of an active human histone pre-mRNA 3′-end processing machinery
Sun, Y., Aik, W. S., Yang, X. C., Marzluff, W. F., Dominski, Z. & Tong, L., 25 Jun 2021, mRNA 3' End Processing and Metabolism. Tian, B. (ed.). 1st ed. Academic Press Inc., p. 291-324 34 p. (Methods in Enzymology; vol. 655).Research output: Chapter in book/report/conference proceeding › Chapter › peer-review
-
Ribonucleoproteins for RNA Therapeutics Delivery
AIK, W. S., 16 Sep 2021, IPC No. C12-AW-U4RN-PT01, 12 Mar 2021, Priority date 13 Mar 2020, Priority No. PCT/CN2021/080443Research output: Patent
-
Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir
Lo, H. S., Hui, K. P. Y., Lai, H. M., He, X., Khan, K. S., Kaur, S., Huang, J., Li, Z., Chan, A. K. N., Cheung, H. H. Y., Ng, K. C., Ho, J. C. W., Chen, Y. W., Ma, B., Cheung, P. M. H., Shin, D., Wang, K., Lee, M. H., Selisko, B., Eydoux, C. & 15 others, , 26 May 2021, In: ACS Central Science. 7, 5, p. 792-802 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus)